spacer
home > ebr > spring 2019 > pricing clinical research in the canadian industry
PUBLICATIONS
European Biopharmaceutical Review

Pricing Clinical Research in the Canadian Industry

The Canadian federal and provincial governments have shown a considerable interest in pharmaceutical R&D, including basic and applied research. Federal agencies have measured both types of research using a cost-of-production approach, including expenditures on materials, supplies, and labour and depreciation on capital. They have used these basic measures to gauge the resources that were used by industry to achieve progress in innovation. Other benefits can be derived from R&D, especially from clinical (patient-included) research and clinical trials. In industry-funded clinical research, companies pay for both the medicines and clinical services provided to the trial enrolees, replacing both public and private payments. The cost concepts that are used to measure the market impact of pharma R&D are very different to those used in government policy documents.

The importance of the market concept of ‘replacement cost’ is that it provides an indicator of the degree to which industry ‘subsidises’ healthcare through its clinical research, including publicly funded care. This concept has largely been lost when considering the role of industry in the healthcare system.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Dat T Tran is a pharmacist by training and has a PhD in health services and policy research, as well as a master of science in pharmacy from the Hanoi University of Pharmacy, Vietnam, master of public health from the University of Sydney, Australia, and a PhD at the University of Alberta, Canada. His research interests lie at the confluence of health and economic perspectives of decision-making against a backdrop of limited healthcare resources.

Dr Ilke Akpinar has a Doctor of Medicine from the University of Ankara, Turkey, and has completed a paediatric surgery residency at the University of Akdeniz, Turkey. She has a master of science in health policy research, specialising in health economics from the School of Public Health, University of Alberta. She has over five years of applied research experience in Canada, with more than 10 years of clinical experience as a paediatric surgeon in Turkey. Ilke’s research interests include health outcomes and health services research, with a particular interest in the cost of clinical trials for medical devices and pharmaceuticals, economic evaluations for chronic diseases, and screening programmes.

Dr Philip Jacobs is a Professor of health economics in the Faculty of Medicine at the University of Alberta, Canada. He received his PhD in economics from the University of York, UK, and was a Cost Accountant. Philip’s research is in the area of healthcare finance and economic evaluations of drugs, vaccines, and medical devices. He was the codeveloper of the healthcare costing document for the Canadian Agency for Drugs and Technologies in Health and has conducted economic evaluations of clinical trials for vaccines, cancer drugs, intensive care, and neonatal intensive care.
spacer
Dr Dat T Tran
spacer
spacer
spacer
Dr Ilke Akpinar
spacer
spacer
spacer
Dr Philip Jacobs
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals and Nordic Nanovector have extended partnership for Betalutin® late stage manufacturing for B-cell non-Hodgkin lymphoma (NHL) treatment

The non-Hodgkin lymphoma (NHL) is a cancer that starts in white blood cells called lymphocytes, which are part of the body’s immune system
More info >>

White Papers

The BioPharmaSpec Approach”: Mass Spectrometry Based Host Cell Protein Identification and Quantitation

BioPharmaSpec

1. Introduction As part of the development of any biopharmaceutical product, the impurities present must be examined, minimized and where possible characterized (1). These impurities fall into two broad categories: product-related impurities (derived specifically from the drug product itself) and process-related impurities (derived from material associated with the production, processing or purification of the sample). Host cell proteins (HCPs) are process-related impurities that require specific analysis due to the multitude of naturally occurring proteins expressed in the production cell line.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement